As of November 6, 2026, TriSalus Life Sciences, Inc. is a publicly traded company (Nasdaq: TLSI). The largest holder reporting an active stake on Schedule 13D is Frankenius Equity AB, at 14%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Mats Wahlstrom, a director (6%) (Schedule 13D/A, August 4, 2025).
Is this your company?
About to sign with, pay or invest in TriSalus Life Sciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is TriSalus Life Sciences, Inc. a real, registered company?
- TriSalus Life Sciences, Inc. files with the SEC under CIK 1826667 (its SEC filings).
- Its shares are listed under the ticker TLSI on Nasdaq (also TLSIW) (SEC company record).
- Incorporated in Delaware; business address in Westminster, Colorado, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under TriSalus Life Sciences, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Jodi Devlin (Form 8-K filed 2026-04-29). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names First Light Asset Management, LLC (filed 2026-07-07).
Who are TriSalus Life Sciences, Inc.'s owners and officers?
TriSalus Life Sciences, Inc.: incorporated in Delaware; business address in Westminster, Colorado; industry Surgical & Medical Instruments & Apparatus (Schedule 13G/A, 2026-07-07).
Officers and directors, each with the role and the filing that names them:
- : Director (Form D, 2025-05-08)
- : Executive Officer, Director (Form D, 2025-05-08)
- : Executive Officer (Form D, 2025-05-08)
- : Director (Form D, 2025-05-08)
- : Director (Form D, 2025-05-08)
- : Director (Form D, 2025-05-08)
- : Director (Form D, 2025-05-08)
- : Director (Form D, 2025-05-08)
- : Executive Officer (Form D, 2025-05-08)
- : Director (Form D, 2025-05-08)
- : Director (Form D, 2025-05-08)
- : Executive Officer (Form D, 2025-05-08)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-07-07 | First Light Asset Management, LLC | 10.74% |
| Schedule 13G/A, 2026-05-20 | James J. Pallotta | 5.2% |
| Schedule 13G, 2026-05-15 | First Light Asset Management, LLC | 8.75% |
| Schedule 13G, 2026-05-12 | Utmost Group PLC | 5.71% |
| Schedule 13G/A, 2025-11-14 | Nantahala Capital Management, LLC | 4.09% |
| Schedule 13G, 2025-11-03 | Utmost Group PLC | 6.79% |
| Schedule 13G, 2025-08-18 | Utmost Group PLC | 0.05% |
| Schedule 13G, 2025-08-14 | Nantahala Capital Management, LLC | 5.29% |
| Schedule 13D/A, 2025-08-04 | Frankenius Equity Ab | 14% |
| Schedule 13D/A, 2025-08-01 | Mats Wahlstrom | 6% |
Questions about who owns TriSalus Life Sciences, Inc.
Who owns TriSalus Life Sciences, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of TriSalus Life Sciences, Inc.: Frankenius Equity Ab (14%, Schedule 13D/A, filed 2025-08-04), First Light Asset Management, LLC (10.74%, Schedule 13G/A, filed 2026-07-07), Mats Wahlstrom (6%, Schedule 13D/A, filed 2025-08-01), Utmost Group PLC (5.71%, Schedule 13G, filed 2026-05-12) and James J. Pallotta (5.2%, Schedule 13G/A, filed 2026-05-20).
Who are the largest shareholders of TriSalus Life Sciences, Inc.?
By the share each holder's latest filing reports, the largest holders of TriSalus Life Sciences, Inc. on this page are Frankenius Equity Ab (14%), First Light Asset Management, LLC (10.74%) and Mats Wahlstrom (6%).
When did Frankenius Equity Ab buy into TriSalus Life Sciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Frankenius Equity Ab on this page is the Schedule 13D/A, filed 2025-08-04, reporting 14%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on TriSalus Life Sciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on TriSalus Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TriSalus Life Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-29 | Jodi Devlin | departed | 2026-10-01 |
Which insiders own TriSalus Life Sciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Frankenius Equity AB, a 10% owner: 6,989,748 shares (11.4% of shares outstanding) (Form 4, 2026-04-20).
- , a director: 2,962,030 shares (4.8% of shares outstanding), 147,555 held directly and 2,814,475 indirectly (Form 4, 2026-05-18).
- , a director: 2,317,400 shares (3.8% of shares outstanding), 542,790 held directly and 1,774,610 indirectly (Form 4, 2026-05-15).
- , a director: 1,640,420 shares (2.7% of shares outstanding), 1,240,722 held directly and 399,698 indirectly (Form 4, 2026-05-18).
- , a director: 1,323,210 shares (2.1% of shares outstanding) (Form 4, 2026-05-15).
Shares outstanding: 61,574,600 as of 2026-08-04, from the company's latest SEC cover page.
How much has TriSalus Life Sciences, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-05-08 | $22M | $22M |
| Form D, 2024-12-30 | $1000K | $1000K |
| Form D, 2023-06-22 | $17.86M | $50M |
Keep reading
More on TriSalus Life Sciences, Inc. and the records around it.
TriSalus Life Sciences, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Leadership changes Apr 2026
- Form D filing May 2025
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
- Nantahala Capital Management, LLC also filed stake reports on 70 other companies: Research Alliance Corp III (Oct 2026), ADC Therapeutics SA (Aug 2026), Anteris Technologies Global Corp. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/trisalus-life-sciences